BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 144557)

  • 1. Chemotherapy of human colon cancer xenografts in athymic nude mice.
    Osieka R; Houchens DP; Goldin A; Johnson RK
    Cancer; 1977 Nov; 40(5 Suppl):2640-50. PubMed ID: 144557
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
    Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of PALA in advanced large bowel carcinoma.
    Rubin J; Purvis J; Britell JC; Hahn RG; Moertel CG; Schutt AJ
    Cancer Treat Rep; 1981; 65(3-4):335-6. PubMed ID: 6453645
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
    Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
    [No Abstract]   [Full Text] [Related]  

  • 8. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM; Anderson LW; Erlichman C; Cysyk RL
    Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of human tumor xenografts in genetically athymic mice.
    Ovejera AA; Houchens DP; Barker AD
    Ann Clin Lab Sci; 1978; 8(1):50-6. PubMed ID: 623430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 11. Modulation of the activity of PALA by dipyridamole.
    Chan TC; Young B; King ME; Taetle R; Howell SB
    Cancer Treat Rep; 1985 Apr; 69(4):425-30. PubMed ID: 3857969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy of metastasizing cancers of the colon and rectum].
    Piedbois P; Lévy E; Le Bourgeois JP; Buyse M
    Ann Chir; 1993; 47(6):480-3. PubMed ID: 7692804
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
    Leung SW; Fung KP; Choy YM; Lee CY
    Cancer Lett; 1984 Jun; 23(2):183-8. PubMed ID: 6744243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
    Martin DS; Stolfi RL; Sawyer RC; Young CW
    Cancer Treat Rep; 1985 Apr; 69(4):421-3. PubMed ID: 3888389
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas.
    Corbett TH; Griswold DP; Roberts BJ; Peckham JC; Schabel FM
    Cancer; 1977 Nov; 40(5 Suppl):2660-80. PubMed ID: 922705
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Natale RB; Yagoda A; Kelsen DP; Gralla RJ; Watson RC
    Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II evaluation of PALA in patients with advanced head and neck cancer.
    Creagan ET; Nichols WC; O'Fallon JR
    Cancer Treat Rep; 1981; 65(9-10):827-9. PubMed ID: 7273014
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.
    Ettinger DS; Tritchler D; Earhart R; Creech RH
    Cancer Treat Rep; 1984 Oct; 68(10):1297-8. PubMed ID: 6525602
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of PALA in patients with metastatic lung cancer.
    Creagan ET; Eagan RT; Fleming TR; Frytak S; Nichols WC; Ingle JN; Kvols LK
    Cancer Treat Rep; 1981; 65(3-4):356-7. PubMed ID: 7237459
    [No Abstract]   [Full Text] [Related]  

  • 20. [Chemotherapy in cancers of the colon].
    Seitz JF
    Gastroenterol Clin Biol; 1993; 17(2 Pt 3):T2-12. PubMed ID: 7686868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.